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Introduction
Juvenile Dermatomyositis (JDM) is the most common
idiopathic inflammatory myopathy in childhood, a sys-
temic vasculopathy that affects usually skin, skeletal mus-
cle, gastrointestinal tract and other organs. The diagnosis
is made by criteria and the goals of treatment include
control the underlying myositis and prevent disease and
treatment complications. Stepwise aggressive treatment
decrease long term sequelae and improve outcomes with
a more rapid normalization of muscle inflammation.
Methods
We studied demographics, epidemiology, clinical and
laboratory characteristics in a descriptive observational
study of 18 children with JDM assisted at our hospital
from January 2000 to November 2010.
Results
72.2% of patients were females. Mean age at disease
onset was 7.36 years. Most common presenting features
were cutaneous and weakness. Medium time between
first signs/symptoms and diagnosis was 59 days. 81.2%
had pathological CK at diagnosis. CMAS was pathologi-
cal in 85.7% of patients, electromyography in 84.61%
and magnetic resonance image (MRI) in all patients that
was made. Muscular biopsy was compatible with JDM
in 83.33%. Medium time between first symptoms and
treatment beginning was 1.94 months. Drugs more fre-
quently used were corticosteorids, methotrexate, hidrox-
icloroquine and intravenosus immunoglobulines. Time
to response was 7.12 months. 50% of patients had dis-
ease relapse (66.6% of them with normal muscular
enzymes) and medium time for it was 6.63 months.
Actually, 7/16 patients have reached clinical remission,
6/16 complete clinical response, 2/16 clinical response.
Conclusions
1. Other myositis-enzymes than CK should be tested at
diagnosis.
2. MRI could evaluate muscular edema with a no
invasive technique.
3. Muscular enzymes are a good tool to monitor dis-
ease activity but in some patients won’t be useful, so we
have to consider MRI and other activity markers.
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